This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2024 Jan 13;403(10422):117.

doi: 10.1016/S0140-6736(24)00047-3.

Time for renewed optimism for schizophrenia?

PMID: 38218604
DOI: 10.1016/S0140-6736(24)00047-3

Editorial

Time for renewed optimism for schizophrenia?

The Lancet. Lancet. 2024.

. 2024 Jan 13;403(10422):117.

doi: 10.1016/S0140-6736(24)00047-3.

Author

PMID: 38218604
DOI: 10.1016/S0140-6736(24)00047-3

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK. Kaul I, et al. Lancet. 2024 Jan 13;403(10422):160-170. doi: 10.1016/S0140-6736(23)02190-6. Epub 2023 Dec 14. Lancet. 2024. PMID: 38104575 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information